What if surplus clinical trial supply wasn’t viewed as waste—but as an opportunity?
In global clinical trials, excess comparator stock is often accepted as the cost of managing risk. But when studies end, valuable commercial medicines are frequently destroyed despite remaining eligible for compliant recovery.
At ClientPharma, we believe there is a better way.
Our Sustainability via Waste Recovery program helps sponsors recover value from eligible surplus stock through compliant repatriation, resale or donation—reducing unnecessary waste while strengthening both sustainability and financial performance.
We help sponsors:
Reduce unnecessary commercial drug destruction
Recover value from eligible surplus inventory
Reinvest recovered capital into future R&D and clinical programs
Sustainability isn’t just about reducing environmental impact—it’s about making smarter decisions with valuable clinical assets.
If you’re looking to maximize the value of our clinical supply while supporting your ESG objectives, we’d love to start the conversation.
Neus Ripoll Torres (Business Development Director (US East Coast)) —
neus.ripolltorres@clientpharma.com
Jeremy Plate (Business Development Director (US West Coast)) —
jeremy.plate@clientpharma.com
Massimo Corbari (Business Development Director (EU)) — massimo.corbari@clientpharma.com
Reclaiming Value from Excess Stock
Posted on
